Inactive Instrument

Highlights Altimmune Inc Nasdaq

Equities

US02155H1014

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Altimmune, Inc. Presents Data at EASL International Liver Congress?? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis	06-05	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000	05-09	MT
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
North American Morning Briefing : More Earnings -2-	04-30	DJ
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B	03-27	MT
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-27	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q4 Revenue $37,000	03-27	MT
North American Morning Briefing : Inflation Data -2-	03-12	DJ
Drugmakers deepen efforts to tap into booming market for obesity drugs	02-27	RE
Zealand shares surge on liver drug data from Boehringer pact	02-26	RE
Altimmune shares slide after Kerrisdale Capital takes short position	02-13	RE
Weight loss drug windfall attracts pharma companies	01-11	RE
Drugmakers plot way into obesity market with deals and development	01-11	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	12-04	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	12-04	RE
Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide	11-30	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q3 Revenue $362,000	11-07	MT
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Altimmune Gets FDA Fast Track Label for Pemvidutide to Treat Non-Alcoholic Steatohepatitis	23-10-26	MT
Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis	23-10-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Altimmune Inc Nasdaq

Equities

US02155H1014

Highlights

Filters